# An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

> **NCT01750216** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 196 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01750216
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01750216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01750216, "An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01750216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*